Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Feb;130(2):222-228.
doi: 10.1016/j.amjmed.2016.08.017. Epub 2016 Sep 2.

Impact of Body Mass Index and Genetics on Warfarin Major Bleeding Outcomes in a Community Setting

Ragan Hart  1 , David L Veenstra  2 , Denise M Boudreau  3 , Joshua A Roth  4
Affiliations

Impact of Body Mass Index and Genetics on Warfarin Major Bleeding Outcomes in a Community Setting

Ragan Hart et al. Am J Med. 2017 Feb.

Abstract

Background: Several studies have demonstrated an association between body mass index (BMI) and warfarin therapeutic dose, but none evaluated the association of BMI with the clinically important outcome of major bleeding in a community setting. To address this evidence gap, we conducted a case-control study to evaluate the association between BMI and major bleeding risk among patients receiving warfarin.

Methods: We used a case-control study design to evaluate the association between obesity (BMI >30.0 kg/m2) and major bleeding risk among 265 cases and 305 controls receiving warfarin at Group Health, an integrated healthcare system in Washington State. Multivariate logistic regression was used to adjust for potential confounders derived from health plan records and a self-report survey. In exploratory analyses we evaluated the interaction between genetic variants potentially associated with warfarin bleeding (CYP2C9, VKORC1, and CYP4F2) and obesity on the risk of major bleeding.

Results: Overall, the sample was 55% male, 94% Caucasian, and mean age was 70 years. Cases and controls had an average of 3.4 and 3.7 years of warfarin use, respectively. Obese patients had significantly lower major bleeding risk relative to non-obese patients (odds ratio [OR] 0.60, 95% confidence interval [CI] 0.39-0.92). The OR was 0.56 (95% CI 0.35-0.90) in patients with ≥1 year of warfarin use, and 0.78 (95% CI 0.40-1.54) in patients with <1 year of warfarin use. An exploratory analysis indicated a statistically significant interaction between CYP4F2*3 genetic status and obesity (P = .049), suggesting a protective effect of obesity on the risk of major bleeding among those wild type for CYP4F2*3, but not among variants.

Conclusions: Our findings suggest that BMI is an important clinical factor in assessing and managing warfarin therapy. Future studies should confirm the major bleeding associations, including the interaction between obesity and CYP4F2*3 status identified in this study, and evaluate potential mechanisms.

Keywords: Body mass index; CYP2C9; CYP4F2; Gene–environment interaction; Major bleeding; VKORC1; Warfarin.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Deitelzweig S. Care Transitions in Anticoagulation Management for Patients With Atrial Fibrillation: An Emphasis on Safety. The Ochsner Journal. 2013;13:419–427. - PMC - PubMed
    1. Fang MC, Go AS, Hylek EM, et al. Age and the Risk of Warfarin-Associated Hemorrhage: The Anticoagulation and Risk Factors In Atrial Fibrillation Study. J Am Geriatr Soc. 2006;54:1231–1236. - PMC - PubMed
    1. Han Z-H, Ren X-J, Wang Y. Anticoagulation management of patients with long-term warfarin therapy after valve replacement during the perioperative period of pacemaker implantation. Int J Clin Exp Med. 2013;6:594–598. - PMC - PubMed
    1. Kamali F, Wynne H. Pharmacogenetics of Warfarin. Annual Review of Medicine. 2010;61:63–75. - PubMed
    1. Moyer TP, O’Kane DJ, Baudhuin LM, et al. Warfarin Sensitivity Genotyping: A Review of the Literature and Summary of Patient Experience. Mayo Clin Proc. 2009;84:1079–1094. - PMC - PubMed